Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alnylam, Kiadis, Puma, Translate Bio.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arcus, Dialectic, Novavax, Promis, Pvp Biologics, Taiho, Takeda, Tonix.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Actinium, Akcea, Amgen, Apeiron, Bayer, Cyclo, Cytokinetics, Exelixis, Fulcrum, GT Biopharma, Inflarx, Ionctura, Menlo, Oramed, Seelos, Sellas, Servier, Vanda, Zynerba.

Biopharmas raising money in public or private financings, including: Aptorum, Genmab, MPM Capital, Outlook.

Quarterly snapshots from biopharma companies with marketed products, including: Amarin, Jazz, United Therapeutics, Vanda.

New hires and promotions in the biopharma industry, including: Curevac, Nordic Nanovector, Nouscom, Summit.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 1st Biotherapeutics, Arecor, Artizan, Astrazeneca, Atrin, Auris, Axovant, Certara, Daiichi Sankyo, Domainex, Dyadic, Excellerate, Immunos, In Silico, Index, Kahr, Lipocine, Lunac, Mallinckrodt, Moderna, Nektar, Omass, Oncologie, Peptilogics, Point Predictive Technology Group, Probiogen, Promis, Proteostasis, Redhill, Roche, Spring Bank, Tetra, Trianni, Twoxar, Vir, Wuxi.

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ascentage, Ascletis, Astellas, Bristol-Myers Squibb, Roche, Seattle Genetics, Seqirus, Takeda.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Eisai, Harbour Biomed, Immutep, Isofol Medical, Kowa Research Institute, Molecular Templates, Ribomic, Zelira.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Biolexis, Canbridge, Outlook.